203 related articles for article (PubMed ID: 27832200)
1. A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer.
Gupta S; Chaudhary K; Dhanda SK; Kumar R; Kumar S; Sehgal M; Nagpal G; Raghava GP
PLoS One; 2016; 11(11):e0166372. PubMed ID: 27832200
[TBL] [Abstract][Full Text] [Related]
2. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
3. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
4. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
5. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
6. In silico tools and databases for designing cancer immunotherapy.
Dhall A; Jain S; Sharma N; Naorem LD; Kaur D; Patiyal S; Raghava GPS
Adv Protein Chem Struct Biol; 2022; 129():1-50. PubMed ID: 35305716
[TBL] [Abstract][Full Text] [Related]
7. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
8. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Sahin U; Derhovanessian E; Miller M; Kloke BP; Simon P; Löwer M; Bukur V; Tadmor AD; Luxemburger U; Schrörs B; Omokoko T; Vormehr M; Albrecht C; Paruzynski A; Kuhn AN; Buck J; Heesch S; Schreeb KH; Müller F; Ortseifer I; Vogler I; Godehardt E; Attig S; Rae R; Breitkreuz A; Tolliver C; Suchan M; Martic G; Hohberger A; Sorn P; Diekmann J; Ciesla J; Waksmann O; Brück AK; Witt M; Zillgen M; Rothermel A; Kasemann B; Langer D; Bolte S; Diken M; Kreiter S; Nemecek R; Gebhardt C; Grabbe S; Höller C; Utikal J; Huber C; Loquai C; Türeci Ö
Nature; 2017 Jul; 547(7662):222-226. PubMed ID: 28678784
[TBL] [Abstract][Full Text] [Related]
9. Computational Methods for Identification of T Cell Neoepitopes in Tumors.
Jurtz VI; Olsen LR
Methods Mol Biol; 2019; 1878():157-172. PubMed ID: 30378075
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics for Cancer Immunotherapy.
Holtsträter C; Schrörs B; Bukur T; Löwer M
Methods Mol Biol; 2020; 2120():1-9. PubMed ID: 32124308
[TBL] [Abstract][Full Text] [Related]
11. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
[TBL] [Abstract][Full Text] [Related]
12. Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy.
Wang M; Yin B; Matsueda S; Deng L; Li Y; Zhao W; Zou J; Li Q; Loo C; Wang RF; Wang HY
PLoS One; 2013; 8(2):e56730. PubMed ID: 23437226
[TBL] [Abstract][Full Text] [Related]
13. Neoepitopes-based vaccines: challenges and perspectives.
Alcazer V; Bonaventura P; Tonon L; Wittmann S; Caux C; Depil S
Eur J Cancer; 2019 Feb; 108():55-60. PubMed ID: 30648630
[TBL] [Abstract][Full Text] [Related]
14. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
15. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
Front Immunol; 2018; 9():99. PubMed ID: 29441070
[TBL] [Abstract][Full Text] [Related]
16. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
Reimann H; Nguyen A; Sanborn JZ; Vaske CJ; Benz SC; Niazi K; Rabizadeh S; Spilman P; Mackensen A; Ruebner M; Hein A; Beckmann MW; van der Meijden ED; Bausenwein J; Kretschmann S; Griffioen M; Schlom J; Gulley JL; Lee KL; Hamilton DH; Soon-Shiong P; Fasching PA; Kremer AN
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172517
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
[TBL] [Abstract][Full Text] [Related]
19. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
20. Prospect and progress of personalized peptide vaccinations for advanced cancers.
Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
